This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance
by Zacks Equity Research
Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 12.85% and 5.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New GERM ETF Launched to Tap the Growing Biotech Sector
by Sweta Killa
GERM invests in the hottest emerging biotechnology trends.
Alnylam???s Share Price Rises YTD on Pipeline Developments
by Zacks Equity Research
Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.
Alnylam Reports Positive Phase III Results on Lumasarin
by Zacks Equity Research
Alnylam (ALNY) reports positive phase III results from the ILLUMINATE-A study on lumasiran.
Why Is Alnylam (ALNY) Down 6.8% Since Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA
by Zacks Equity Research
Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALNY) Outperforming Other Medical Stocks This Year?
How Alnylam (ALNY) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Alnylam (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Makes Alnylam (ALNY) a New Buy Stock
by Zacks Equity Research
Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALNY) Outperforming Other Medical Stocks This Year?
Alnylam (ALNY) Beats on Q1 Earnings, Cuts Onpattro Sales View
by Zacks Equity Research
Alnylam (ALNY) loss narrows in Q1. It beats sales estimates but cuts guidance for product revenues from Onpattro due to potential impact of COVID-19.
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 14.29% and 9.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Is a Surprise Coming for Alnylam Pharmaceuticals (ALNY) This Earnings Season?
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2020 results.
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) will provide pipeline updates along with financial numbers for the first quarter in its impending earnings release.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease